Botox vs. Dysport: REMS is a New wrinkle in Big Market

A marketing battle with an unusual twist is brewing between Allergan's popular anti-wrinkle agent Botox and new-to-the-block Dysport, from Ipsen-Medicis. Both sides are citing their REMS (Risk Evaluation and Mitigation Strategy) as a key competitive advantage.

A marketing battle with an unusual twist is brewing between Allergan Inc.’s popular anti-wrinkle agent Botox and Ipsen/Medicis Pharmaceutical Corp.’s new-to-the-block Dysport: both sides are citing their REMS as a key competitive advantage.

The REMS (Risk Evaluation and Mitigation Strategy) program is turning out to be a weapon of choice because it gives...

More from Archive

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.